

Application No.: 09/975,136

6

Docket No.: 524022000100

REMARKS

Upon entry of the present Amendment, claims 1-3 and 5-21 will be pending. Claim 4 is canceled. Applicants reserve the rights to pursue the withdrawn and/or canceled subject matter in a subsequent application. The above-described amendments do not introduce any new matter into the present application.

Allowable Subject Matter and Withdrawn Rejections/Objections

Applicants appreciate the Examiner's statement that claims 2, 4, 10, 12 and 18 are drawn to allowable subject matter and claims 5-9, 11, 13-17 and 19-21 are allowed. Applicants also appreciate the Examiner's withdraw of the following rejections and objections:

- The objection to the specification set forth in paragraph 11 of the previous Office Action in Paper No 10 is withdrawn in response to Applicant's amendment.
- The objection to the claims set forth in this paragraph 12 of the previous Office Action in Paper No 10 is withdrawn in response to Applicant's amendment.
- The rejections under 35 USC § 112, second paragraph, set forth in paragraph 13 of the previous Office Action in Paper No 10 is withdrawn in response to Applicant's amendment.
- The rejection under 35 USC § 103 set forth in paragraph 14 of the previous Office Action in Paper No 10 is withdrawn in response to Applicants' argument (Page 7, amendment, 3rd full paragraph).

sd-159546


Application No.: 09/975,136

7

Docket No.: 524022000100

Claim Rejections - 35 USC § 102

Claims 1, 3 and 4 are rejected under 35 U.S.C. 102(b) as allegedly being anticipated by Sperl et al (Proceedings of the National Academy of Sciences of the United States of America, (4-aminomethyl) Phenylguanidine Derivatives an Nonpeptidic Highly Selective Inhibitors of Human Urokinase 2000, 97 (10), pages 5113-5118. Sperl discloses (Page 5114, column 1, Table 1, entry 2) the following structure:



This allegedly corresponds to a compound of the instantly claimed genus of claim 1 in which $n=0$; $R = C_5$ alkyl. Sperl further allegedly discloses (Page 5114, column 1, Table 1, entry 2, columns 3-5) enzyme assays of these compounds. These assay solutions of the compound allegedly correspond to pharmaceutical compositions of the compound in a pharmaceutically acceptable carrier (water). Claims 1, 3 and 4 are therefore allegedly anticipated by Sperl.

As agreed upon in the August 7, 2003 interview, this rejection is rendered moot by the amendment of claim 1.

Claim Objections

The Examiner also made the following objections in the June 13, 2002 Office Action:

- Claim 2 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.
- Claim 4 is objected to because of the following informalities: The word "pharmaceutically" on line 1 should be changed to "pharmaceutical".

sd-159546

Application No.: 09/975,136

8

Docket No.: 524022000100

- Claim 10 is objected to because of the following informalities: The word "be" should be added after the word "to" on line 2.
- Claim 12 is objected to because of the following informalities: The word "a" should be added after the word "is" on line 1.
- Claim 18 is objected to because of the following informalities: The second word "to" on line 2 should be changed to the word "for".

As agreed upon in the August 7, 2003 interview, these objections are rendered moot by the cancellation of claim 4 and the amendments of claims 2, 10, 12 and 18.

sd-159546

Application No.: 09/975,136

9

Docket No.: 524022000100


CONCLUSION

As agreed upon in the August 7, 2003 interview, the anticipation rejection and other objections are overcome by the present amendments. Early allowance of the pending claims 1-3 and 5-21 are earnestly requested. If, however, the Examiner believes that three are still unaddressed issues, the undersigned would like to have another telephonic interview to discuss such issues.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 524022000100. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August 8, 2003

Respectfully submitted,

By 
Peng Chen
Registration No.: 43,543
MORRISON & FOERSTER LLP
3811 Valley Centre, Suite 500
San Diego, California 92130
(858) 720-5117
Attorneys for Applicant

sd-159546